Modality
Bispecific Ab
MOA
Menini
Target
CDK4/6
Pathway
Notch
LN
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
→ Oct 2026
Phase 1Current
NCT03395372
641 pts·LN
2023-12→2026-10·Completed
NCT04580983
131 pts·LN
2018-11→TBD·Not yet recruiting
772 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-016mo awayInterim· LN
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Not yet…
P1
Complet…
Catalysts
Interim
2026-10-01 · 6mo away
LN
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03395372 | Phase 1 | LN | Completed | 641 | EDSS |
| NCT04580983 | Phase 1 | LN | Not yet recr... | 131 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Rimanaritide | Agios | Phase 1 | CDK4/6 | |
| TXG-6755 | 10x Genomics | Approved | CD123 |